# Brown Fat Activation Study

> **NCT02919176** · EARLY_PHASE1 · COMPLETED · sponsor: **Philip Kern** · enrollment: 39 (actual)

## Conditions studied

- Obese
- Metabolic Syndrome

## Interventions

- **DRUG:** Mirabegron
- **DRUG:** Pioglitazone
- **DRUG:** Mirabegron and Pioglitazone

## Key facts

- **NCT ID:** NCT02919176
- **Lead sponsor:** Philip Kern
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-01
- **Primary completion:** 2019-02-04
- **Final completion:** 2019-02-04
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2020-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02919176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02919176, "Brown Fat Activation Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02919176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*